FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Ann Hematol / Comparison between horse and rabbit antithymocyte globulin a...
Annals of hematology2010; 89(9); 851-859; doi: 10.1007/s00277-010-0944-y

Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study.

Abstract: The best antithymocyte globulin preparation for first-line immune suppression in patients with severe aplastic anemia is still not clear. The aim of this study was to compare hematological response and overall survival in patients submitted to horse or rabbit antithymocyte globulin as first-line treatment for severe aplastic anemia. We retrospectively compared 71 consecutive patients with severe aplastic anemia, classified according to the antithymocyte globulin preparation. Analyses included variables related to patients and to immune suppression. Forty two patients (59.1%) received horse and 29 (40.9%) rabbit antithymocyte globulin. Response rates were higher at 6 months in patients submitted to horse in comparison to rabbit antithymocyte globulin (59.5% versus 34.5% respectively, p = 0.05). Median time to response was similar between the two groups (99 versus 88.5 days, respectively, for horse and rabbit antithymocyte globulin; p = 0.98). Overall survival at 2 years was significantly higher in patients submitted to horse in comparison to rabbit antithymocyte globulin (78.4% versus 55.4%, p = 0.03). Post-treatment response was strongly associated with survival at 2 years (97% in responders versus 41.2% in non-responders, p < 0.001). Use of rabbit antithymocyte globulin was an independent predictor of death (odds ratio 2.5; 95% confidence interval 1.03-6.04; p = 0.04). Rabbit antithymocyte globulin was associated with a significant and prolonged lymphopenia in comparison with horse antithymocyte globulin. Our data suggest the superiority of horse over rabbit antithymocyte globulin as first-line treatment for severe aplastic anemia, both regarding hematological response and survival.
Get Full Text
Publication Date: 2010-04-07 PubMed ID: 20373101DOI: 10.1007/s00277-010-0944-yGoogle Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Comparative Study
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This research study compares the efficacy of horse and rabbit antithymocyte globulin as a first-line therapy for severe aplastic anemia, finding that treatment with horse globulin showed higher response rates and survival rates at 2-year mark.

Background

  • The study was conducted to determine the most effective form of antithymocyte globulin for immune suppression in patients suffering from severe aplastic anemia.

Methodology

  • The research retrospectively compared 71 patients with severe aplastic anemia who have been treated either with horse or rabbit antithymocyte globulin.
  • The variables studied included factors related to the patients and also to the immune suppression.

Findings

  • Out of total participants, 59.1% were treated with horse globulin and 40.9% with rabbit globulin.
  • Patients who were given horse globulin demonstrated higher response rates at 6-month period when compared to those who were given rabbit globulin (59.5% versus 34.5%).
  • The median time to response was found to be similar in both the groups (99 and 88.5 days for horse and rabbit globulin respectively).
  • Overall survival at 2 years was significantly higher in the horse globulin patients in comparison to the rabbit globulin ones (78.4% versus 55.4%).

Conclusion

  • Post-treatment response was strongly related to 2-year survival rates, with 97% among responders versus 41.2% in non-responders.
  • Rabbit globulin usage was independently linked to higher mortality rates (odds ratio 2.5).
  • Rabbit globulin was associated with a significant and prolonged lymphopenia when compared to horse globulin.
  • The data from the research suggests that horse antithymocyte globulin may be superior to rabbit globulin as the first-line treatment for severe aplastic anemia, both in terms of hematological response and survival.

Cite This Article

APA
Atta EH, Dias DS, Marra VL, de Azevedo AM. (2010). Comparison between horse and rabbit antithymocyte globulin as first-line treatment for patients with severe aplastic anemia: a single-center retrospective study. Ann Hematol, 89(9), 851-859. https://doi.org/10.1007/s00277-010-0944-y

Publication

Annals of hematology
ISSN: 1432-0584
NlmUniqueID: 9107334
Country: Germany
Language: English
Volume: 89
Issue: 9
Pages: 851-859

Researcher Affiliations

Atta, Elias Hallack
  • Hematopoietic Stem Cell Program, Hemorio, Rua Frei Caneca 8, Rio de Janeiro, RJ, Brazil. elias.atta@hemorio.rj.gov.br
Dias, Danielle Saldanha Peixoto
    Marra, Vera Lúcia Neves
      de Azevedo, Alexandre Mello

        MeSH Terms

        • Adolescent
        • Adult
        • Aged
        • Anemia, Aplastic / drug therapy
        • Anemia, Aplastic / mortality
        • Animals
        • Antilymphocyte Serum / adverse effects
        • Antilymphocyte Serum / therapeutic use
        • Child
        • Child, Preschool
        • Female
        • Horses
        • Humans
        • Infant
        • Lymphopenia / chemically induced
        • Male
        • Middle Aged
        • Rabbits
        • Retrospective Studies
        • Severity of Illness Index
        • Species Specificity
        • Survival Rate / trends
        • T-Lymphocytes / immunology
        • Treatment Outcome
        • Young Adult

        Citations

        This article has been cited 33 times.
        1. Yang W, Liu X, Zhao X, Zhang L, Peng G, Ye L, Zhou K, Li Y, Li J, Fan H, Yang Y, Xiong Y, Jing L, Zhang F. Antihuman T lymphocyte porcine immunoglobulin combined with cyclosporine as first-line immunosuppressive therapy for severe aplastic anemia in China: a large single-center, 10-year retrospective study. Ther Adv Hematol 2023;14:20406207221146031.
          doi: 10.1177/20406207221146031pubmed: 36654738google scholar: lookup
        2. Norasetthada L, Wongkhantee S, Chaipokam J, Charoenprasert K, Chuncharunee S, Rojnuckarin P, Sirijerachai C, Wanachiwanawin W, Issaragrisil S. Adult aplastic anemia in Thailand: incidence and treatment outcome from a prospective nationwide population-based study. Ann Hematol 2021 Oct;100(10):2443-2452.
          doi: 10.1007/s00277-021-04566-0pubmed: 34269837google scholar: lookup
        3. Huang J, Huang L, Liu S, Lin S, Cheng Y, Jiang X, Xue H, Li C, Chen C. Clinical Outcome of Acquired Post-Immunosuppressive-Therapy Aplastic Anemia in Pediatric Patients: A 13-Year Experience in Two Southern China Tertiary Care Centers. Int J Gen Med 2021;14:3133-3144.
          doi: 10.2147/IJGM.S313898pubmed: 34239322google scholar: lookup
        4. Imada K, Obara N, Iida H, Imajo K, Maeda T, Usuki K, Fanghong Z, Hombo Y, Tajima T, Kumagai A, Matsuda A, Nakao S. Eltrombopag in Combination with Rabbit Anti-thymocyte Globulin/Cyclosporine A in Immunosuppressive Therapy-naïve Patients with Aplastic Anemia in Japan. Intern Med 2021 Apr 15;60(8):1159-1168.
          doi: 10.2169/internalmedicine.6063-20pubmed: 33229810google scholar: lookup
        5. Lan Y, Chang L, Yi M, Cai Y, Feng J, Ren Y, Liu C, Chen X, Wang S, Guo Y, Zhang A, Liu L, Zhang J, Zhu X. Long-term outcomes of 172 children with severe aplastic anemia treated with rabbit antithymocyte globulin and cyclosporine. Ann Hematol 2021 Jan;100(1):53-61.
          doi: 10.1007/s00277-020-04296-9pubmed: 33033910google scholar: lookup
        6. Jiang J, Cai Y, Wan L, Yang J, Wang C. Cord blood infusion-accelerated hematopoietic recovery after combined immunosuppressive therapy with fludarabine and rabbit ATG in severe aplastic anemia. Int J Hematol 2020 Mar;111(3):360-368.
          doi: 10.1007/s12185-019-02807-7pubmed: 31900878google scholar: lookup
        7. Siddiqui S, Cox J, Herzig R, Palaniyandi S, Hildebrandt GC, Munker R. Anti-thymocyte globulin in haematology: Recent developments. Indian J Med Res 2019 Sep;150(3):221-227.
          doi: 10.4103/ijmr.IJMR_752_19pubmed: 31719292google scholar: lookup
        8. Shah S, Jain P, Shah K, Patel K, Parikh S, Patel A, Panchal H, Anand A. Immunosuppressive therapy for aplastic anemia: a single-center experience from western India. Ann Hematol 2019 Jan;98(1):41-46.
          doi: 10.1007/s00277-018-3487-2pubmed: 30173288google scholar: lookup
        9. Hayakawa J, Kanda J, Akahoshi Y, Harada N, Kameda K, Ugai T, Wada H, Ishihara Y, Kawamura K, Sakamoto K, Ashizawa M, Sato M, Terasako-Saito K, Kimura SI, Kikuchi M, Yamazaki R, Kako S, Kanda Y. Meta-analysis of treatment with rabbit and horse antithymocyte globulin for aplastic anemia. Int J Hematol 2017 May;105(5):578-586.
          doi: 10.1007/s12185-017-2179-3pubmed: 28078653google scholar: lookup
        10. Chuncharunee S, Wong R, Rojnuckarin P, Chang CS, Chang KM, Lu MY, Hwang WL, Koh LP, Chen TY, Leung AY, Norasetthada L, Wang SC, Chang MC, Wu KH, Issaragrisil S. Efficacy of rabbit antithymocyte globulin as first-line treatment of severe aplastic anemia: an Asian multicenter retrospective study. Int J Hematol 2016 Oct;104(4):454-61.
          doi: 10.1007/s12185-016-2053-8pubmed: 27376944google scholar: lookup
        11. Suzuki T, Kobayashi H, Kawasaki Y, Okazuka K, Hatano K, Fujiwara S, Oh I, Ohmine K, Kanda Y. Efficacy of combination therapy with anti-thymocyte globulin and cyclosporine A as a first-line treatment in adult patients with aplastic anemia: a comparison of rabbit and horse formulations. Int J Hematol 2016 Oct;104(4):446-53.
          doi: 10.1007/s12185-016-2046-7pubmed: 27338268google scholar: lookup
        12. Yang L, Wang H, Shao Z. [Advances in the treatment of severe aplastic anemia]. Zhonghua Xue Ye Xue Za Zhi 2015 Aug;36(8):711-5.
          doi: 10.3760/cma.j.issn.0253-2727.2015.08.021pubmed: 26462649google scholar: lookup
        13. Takahashi T, Maruyama Y, Saitoh M, Itoh H, Yoshimoto M, Tsujisaki M. Fatal Epstein-Barr Virus Reactivation in an Acquired Aplastic Anemia Patient Treated with Rabbit Antithymocyte Globulin and Cyclosporine A. Case Rep Hematol 2015;2015:926874.
          doi: 10.1155/2015/926874pubmed: 26425376google scholar: lookup
        14. Bleyzac N, Philippe M, Bertrand A, Bertrand Y. Confounding effect of cyclosporine dosing when comparing horse and rabbit antithymocyte globulin in patients with severe aplastic anemia. Haematologica 2015 May;100(5):e211-2.
          doi: 10.3324/haematol.2014.122275pubmed: 25944638google scholar: lookup
        15. Clé DV, Atta EH, Dias DS, Lima CB, Bonduel M, Sciuccati G, Medeiros LA, de Oliveira MM, Salvino MA, Garanito M, Saad ST, Calado RT, Scheinberg P. Repeat course of rabbit antithymocyte globulin as salvage following initial therapy with rabbit antithymocyte globulin in acquired aplastic anemia. Haematologica 2015 Sep;100(9):e345-7.
          doi: 10.3324/haematol.2015.123760pubmed: 25862703google scholar: lookup
        16. Shin SH, Lee SE, Lee JW. Recent advances in treatment of aplastic anemia. Korean J Intern Med 2014 Nov;29(6):713-26.
          doi: 10.3904/kjim.2014.29.6.713pubmed: 25378968google scholar: lookup
        17. Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y. New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs 2014 Sep;74(14):1605-34.
          doi: 10.1007/s40265-014-0277-6pubmed: 25164240google scholar: lookup
        18. Nakanishi R, Ishida M, Hodohara K, Okuno H, Yoshii M, Horinouchi A, Shirakawa A, Harada A, Iwai M, Yoshida K, Kagotani A, Yoshida T, Okabe H. Occurrence of Epstein-Barr virus-associated plasmacytic lymphoproliferative disorder after antithymocyte globulin therapy for aplastic anemia: a case report with review of the literature. Int J Clin Exp Pathol 2014;7(4):1748-54.
          pubmed: 24817974
        19. Samarasinghe S, Marsh J, Dufour C. Immune suppression for childhood acquired aplastic anemia and myelodysplastic syndrome: where next?. Haematologica 2014 Apr;99(4):597-9.
          doi: 10.3324/haematol.2014.105569pubmed: 24688105google scholar: lookup
        20. Scheinberg P, Townsley D, Dumitriu B, Scheinberg P, Weinstein B, Rios O, Wu CO, Young NS. Horse antithymocyte globulin as salvage therapy after rabbit antithymocyte globulin for severe aplastic anemia. Am J Hematol 2014 May;89(5):467-9.
          doi: 10.1002/ajh.23669pubmed: 24415649google scholar: lookup
        21. Jeong DC, Chung NG, Cho B, Zou Y, Ruan M, Takahashi Y, Muramatsu H, Ohara A, Kosaka Y, Yang W, Kim HK, Zhu X, Kojima S. Long-term outcome after immunosuppressive therapy with horse or rabbit antithymocyte globulin and cyclosporine for severe aplastic anemia in children. Haematologica 2014 Apr;99(4):664-71.
          doi: 10.3324/haematol.2013.089268pubmed: 24213150google scholar: lookup
        22. Yoshimi A, van den Heuvel-Eibrink MM, Baumann I, Schwarz S, Simonitsch-Klupp I, de Paepe P, Campr V, Kerndrup GB, O'Sullivan M, Devito R, Leguit R, Hernandez M, Dworzak M, de Moerloose B, Stary J, Hasle H, Smith OP, Zecca M, Catala A, Schmugge M, Locatelli F, Führer M, Fischer A, Guderle A, Nöllke P, Strahm B, Niemeyer CM. Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica 2014 Apr;99(4):656-63.
          doi: 10.3324/haematol.2013.095786pubmed: 24162791google scholar: lookup
        23. Ruutu T, Gratwohl A, de Witte T, Afanasyev B, Apperley J, Bacigalupo A, Dazzi F, Dreger P, Duarte R, Finke J, Garderet L, Greinix H, Holler E, Kröger N, Lawitschka A, Mohty M, Nagler A, Passweg J, Ringdén O, Socié G, Sierra J, Sureda A, Wiktor-Jedrzejczak W, Madrigal A, Niederwieser D. Prophylaxis and treatment of GVHD: EBMT-ELN working group recommendations for a standardized practice. Bone Marrow Transplant 2014 Feb;49(2):168-73.
          doi: 10.1038/bmt.2013.107pubmed: 23892326google scholar: lookup
        24. Shin SH, Lee JW. The optimal immunosuppressive therapy for aplastic anemia. Int J Hematol 2013 May;97(5):564-72.
          doi: 10.1007/s12185-013-1331-ypubmed: 23605367google scholar: lookup
        25. Li X, Shi J, Ge M, Shao Y, Huang J, Huang Z, Zhang J, Nie N, Zheng Y. Outcomes of optimized over standard protocol of rabbit antithymocyte globulin for severe aplastic anemia: a single-center experience. PLoS One 2013;8(3):e56648.
          doi: 10.1371/journal.pone.0056648pubmed: 23554855google scholar: lookup
        26. Ram R, Storb R. Pharmacologic prophylaxis regimens for acute graft-versus-host disease: past, present and future. Leuk Lymphoma 2013 Aug;54(8):1591-601.
          doi: 10.3109/10428194.2012.762978pubmed: 23278640google scholar: lookup
        27. Scheinberg P, Young NS. How I treat acquired aplastic anemia. Blood 2012 Aug 9;120(6):1185-96.
          doi: 10.1182/blood-2011-12-274019pubmed: 22517900google scholar: lookup
        28. Kadia TM, Borthakur G, Garcia-Manero G, Faderl S, Jabbour E, Estrov Z, York S, Huang X, Pierce S, Brandt M, Koller C, Kantarjian HM, Ravandi F. Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol 2012 May;157(3):312-20.
          doi: 10.1111/j.1365-2141.2012.09064.xpubmed: 22360602google scholar: lookup
        29. Risitano AM, Perna F. Aplastic anemia: immunosuppressive therapy in 2010. Pediatr Rep 2011 Jun 22;3 Suppl 2(Suppl 2):e7.
          doi: 10.4081/pr.2011.s2.e7pubmed: 22053283google scholar: lookup
        30. Scheinberg P, Nunez O, Weinstein B, Scheinberg P, Biancotto A, Wu CO, Young NS. Horse versus rabbit antithymocyte globulin in acquired aplastic anemia. N Engl J Med 2011 Aug 4;365(5):430-8.
          doi: 10.1056/NEJMoa1103975pubmed: 21812672google scholar: lookup
        31. Afable MG 2nd, Shaik M, Sugimoto Y, Elson P, Clemente M, Makishima H, Sekeres MA, Lichtin A, Advani A, Kalaycio M, Tiu RV, O'Keefe CL, Maciejewski JP. Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica 2011 Sep;96(9):1269-75.
          doi: 10.3324/haematol.2011.042622pubmed: 21606164google scholar: lookup
        32. Viola GM, Zu Y, Baker KR, Aslam S. Epstein-Barr virus-related lymphoproliferative disorder induced by equine anti-thymocyte globulin therapy. Med Oncol 2011 Dec;28(4):1604-8.
          doi: 10.1007/s12032-010-9635-8pubmed: 20680523google scholar: lookup
        33. Xie X, Zhao H, Qin D, Qiao X. Pharmacokinetics and pharmacodynamics of two antithymocyte globulins in treatment of pediatric aplastic anemia. Int J Clin Exp Med 2015;8(3):4349-55.
          pubmed: 26064352
        Subscribe to our newsletter
        Join 99,357 horse owners like you who receive our email updates on horse health and nutrition.